Article Figures & Tables
Tables
- Table 1:
Characteristics of patients who tested positive for severe acute respiratory syndrome coronavirus 2 and control patients
Characteristic No. (%) of patients* Crude OR (95% CI) Control patients
n = 134SARS-CoV-2-positive patients
n = 134Age, yr, median (IQR) 57.2 (42.6–64.4) 57.1 (41.2–64.5) – Sex Female 81 (60.4) 70 (52.2) 1.0 (Ref.) Male 53 (39.6) 64 (47.8) 1.3 (0.8–2.1) Smoking Never smoked 75 (56.0) 75 (56.0) 1.0 (Ref.) Past smoker 46 (34.3) 44 (32.8) 0.9 (0.5–1.7) Active smoker 13 (9.7) 15 (11.2) 1.1 (0.5–2.4) Seasonal allergies 20 (14.9) 16 (11.9) 0.8 (0.4–1.6) Allergy to furry animals 17(12.7) 12 (9.0) 0.6 (0.3–1.5) Year-round nasal congestion 14 (10.4) 18 (13.4) 1.3 (0.6–2.7) Year-round nasal drip 16 (11.9) 15 (11.2) 0.9 (0.4–1.9) Long-term use of nasal corticosteroid sprays No 122 (91.0) 124 (92.5) 1.0 (Ref.) Occasionally 6 (4.5) 3 (2.2) 0.5 (0.1–2..0) Continuous use 6 (4.5) 7 (5.2) 1.2 (0.4–3.5) Signs and symptoms (within 72 h before or after SARS-CoV-2 testing) Anosmia 6 (4.5) 69 (51.5) 32.5 (8.0–132.7) Dysgeusia 9 (6.7) 85 (63.4) 16.2 (6.6–40.0) Anosmia and/or dysgeusia 11 (8.2) 87 (64.9) 20.0 (7.3–54.6) Asthenia 58 (43.3) 104 (77.6) 3.9 (2.2–6.7) Myalgia 29 (21.6) 76 (56.7) 4.9 (2.6–9.2) Arthralgia 19 (14.2) 37 (27.6) 2.2 (1.2–4.1) Chest pain 30 (22.4) 35 (26.1) 1.2 (0.7–2.2) Dyspnea 49 (36.6) 56 (41.8) 1.2 (0.8–2.0) Chills 32 (23.9) 71 (53.0) 2.7 (1.7–4.7) Fever (subjective) 35 (26.1) 46 (34.3) 1.5 (0.9–2.6) Fever (objective) 20 (14.9) 50 (37.3) 2.9 (1.6–5.1) Nasal congestion 56 (41.8) 58 (43.3) 1.1 (0.6–1.9) Nasal drip 73 (54.5) 60 (44.8) 0.6 (0.3–1.0) Sneezing 58 (43.3) 53 (39.6) 0.8 (0.5–1.4) Sore throat 72 (53.7) 60 (44.8) 0.7 (0.4–1.1) Cough 96 (71.6) 97 (72.4) 1.0 (0.6–1.7) Sputum production 43 (32.1) 40 (29.8) 0.9 (0.6–1.5) Loss of appetite 26 (19.4) 75 (56.0) 4.1 (2.4–7.0) Nausea 17 (12.7) 40 (29.8) 2.9 (1.5–5.6) Vomiting 5 (3.7) 9 (6.7) 1.8 (0.6–5.4) Diarrhea 31 (23.1) 60 (44.8) 2.7 (1.6–4.7) Headaches 62 (46.3) 87 (64.9) 2.9 (1.3–3.4) Red eyes 3 (2.2) 1 (0.7) 0.3 (0.0–3.2) Rash 6 (4.5) 8 (6.0) 1.4 (0.4–4.4) Vertigo or dizziness 14 (10.4) 27 (20.1) 2.3 (1.1–4.8) Blurred vision 9 (6.7) 6 (4.5) 0.7 (0.2–1.9) Loss of temperature sensation in face 1 (0.7) 5 (3.7) 5.0 (0.6–42.9) Note: CI = confidence interval, IQR = interquartile range, OR = odds ratio, Ref. = reference, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
↵* Except where noted otherwise.
- Table 2:
Characteristics of patients who tested positive for severe acute respiratory syndrome coronavirus 2 and had anosmia or dysgeusia
Characteristic No. (%) of patients* Self-described change in olfactory capacity (n = 69) Light 6 (9) Moderate 12 (17) Severe 51 (74) Onset of change in olfactory capacity (n = 69) Progressive (over several days) 19 (28) Sudden 50 (72) Capacity to recognize specific odours (n = 69) Perfume Not at all 38 (55) Weak 22 (34) Good 3 (4) Very good 1 (2) Not applicable 5 (7) Smoke Not at all 32 (46) Weak 17 (25) Good 5 (7) Very good 1 (2) Not applicable 14 (20) Garbage Not at all 36 (52) Weak 21 (30) Good 2 (3) Very good 1 (2) Not applicable 9 (13) Coffee Not at all 35 (51) Weak 27 (39) Good 2 (3) Very good 1 (2) Not applicable 4 (6) Modification/alteration in tasting capacity (n = 85) 31 (37) Loss of tasting capacity (n = 85) 68 (81) Onset of change in tasting capacity (n = 85) Progressive (over several days) 33 (39) Sudden 52 (61) Self-described change/alteration in tasting capacity (n = 85) Light 8 (9) Moderate 31 (36) Severe 46 (54) ↵* The number of patients may not be equal to the total number in some categories owing to unknown or missing values.